The Medipattern Corporation

The Medipattern Corporation

November 21, 2007 11:59 ET

Medipattern Launches B-CAD™ 2.2 Worldwide With Multiple Unit Lead Order

TORONTO, ONTARIO--(Marketwire - Nov. 21, 2007) - The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better informed biopsy decisions and to permit a higher standard of care for the millions of patients at risk of breast cancer, is pleased to announce the installation of its latest version of B-CAD, 2.2, at the Instituto Nacional de Cancerologia in Mexico City.

Electronica y Medicina, S.A. (EYMSA), Medipattern's authorized reseller in Mexico, placed a lead order for six B-CAD 2.2 systems and has installed a number of units in hospitals and training facilities throughout Mexico. "B-CAD embodies standardization and increases consistency across radiology practices," said Cuauhtemoc Monroy, President of EYMSA. "Systematically tracking lesions seen via ultrasound is important. B-CAD saves time, increases accuracy, and saves transcription costs. Fighting breast cancer is a priority in Mexico. B-CAD gives our customers the ability to work more efficiently in that fight."

B-CAD 2.2 for breast ultrasound imaging electronically analyzes breast masses using more of the American College of Radiology (ACR) BI-RADS® (Breast Imaging Reporting and Data System) feature categories than ever before, including: size, three feature categories for shape, two for orientation, six for margin, two for lesion boundary, four for echo pattern, four for posterior acoustic features, and one for calcifications in mass. Version 2.2 documents all of the information required to track multiple lesions and completes the procedure by automatically documenting the results. Version 2.2 is production-released and available for immediate shipment.

"Medipattern's technology enhancements in B-CAD 2.2, enabling physicians to identify more lesion characteristics for multiple lesions in the same case, exemplify our commitment to continuously improve the performance and features available in our products. Using B-CAD as part of the breast ultrasound procedure can identify breast lesions so that physicians can act quickly and appropriately for the millions of women already in periodic follow up. We are honored to support the physicians in Mexico and throughout the world who are dedicated to better breast care," said Jeff Collins, CEO of Medipattern.

Upcoming Events:

Medipattern will participate in the following events:

- Radiological Society of North America (RSNA) booth 5515, November 25 to 29, 2007, Chicago, IL.

- European Congress of Radiology, March 7 to 11, Vienna, Austria

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CAD MRI™. Both have received awards for innovation in the industry. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Medipattern was founded to design software products that detect and identify lesions in breast imaging to support a higher standard of medical care. Please visit the company's website at:

B-CAD™ and B-CAD MRI™ are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation. BI-RADS® is a registered trademark of the American College of Radiology.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information